ClinicalTrials.gg
CompletedNCT01011751Updated Jul 30, 2015

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

A Phase 3 interventional study of Cyproterone acetate and Medroxyprogesterone acetate in Adenocarcinoma, Prostate, sponsored by Takeda. Completed at 1 site in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-30.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Adenocarcinoma with a site in France — 15 open to participants now, 25 under way, 6 of them phase 3. Adenocarcinoma · France.

Enrollment
24th of 73
311 · median 162
Started
2004
the only one that year
Phase 3
20 of 83
3 open now
Registered
15th of 83
by date

Among the 83 studies in Adenocarcinoma with a site in France, this one is the 24th largest by enrollment of the 73 interventional ones that give a count, is the only one that started in 2004, is one of 20 in phase 3, and was the 15th registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

15 of the 83 studies in Adenocarcinoma with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Adenocarcinoma with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of three drugs (cyproterone acetate, medroxyprogesterone acetate and venlafaxine) in the treatment of hot flushes caused by leuprorelin LP 11.25 milligram (mg) in participants suffering from prostate cancer.

Read the detailed description

Three drugs will be tested in this study: cyproterone acetate, medroxyprogesterone acetate and venlafaxine. Cyproterone acetate, medroxyprogesterone acetate and venlafaxine are being tested to treat men who suffer from hot flushes due to androgen suppression treatment for prostate cancer. This study will look at the frequency and severity of hot flushes caused by leuprorelin in participants who will take cyproterone acetate, medroxyprogesterone acetate or venlafaxine. The study will randomize approximately 311 participants. All participants will receive 2 injections of leuprorelin 11.35 mg at Months 0 and 3 along with flutamide tablets in the first month of treatment to prevent flare-up. After 6 months, eligible participants will receive third injection of leuprorelin and will be randomly assigned to one of the three treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Cyproterone acetate (Androcur® 50 mg)
  • Medroxyprogesterone acetate (Gestoral® 10 mg)
  • Venlafaxine (Effexor® LP 37.5 mg) All participants will be asked to take 2 capsules in the morning and 1 capsule in the evening for 10 weeks. All participants will be asked to complete the self-evaluation hot-flushes (HF) questionnaire daily for 12 weeks from the start of treatment for hot flushes.

This multi-center trial will be conducted in France. The overall time to participate in this study is approximately 9 months. Participants will make 5 visits to the clinic during the study.

03

Conditions studied

  • Adenocarcinoma, Prostate

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Patient has a proven prostatic adenocarcinoma.

  • Patient has been on a gonadotropin releasing hormone (GnRH) agonist treatment for a duration of at least 1 year.
  • index greater than or equal to (>=) 70 %.
  • Patient who, after having been clearly informed, has given his written consent to participate in the study.

Exclusion Criteria:

  • Patient included in a therapeutic trial in the 3 months preceding the inclusion visit.
  • Prescription of agonist planned in the context of hormonotherapy.
  • Patient has symptomatic bone .
  • Patient already treated with hormonotherapy for his prostate cancer or has received a hormonal treatment other than a GnRH agonist for this cancer (apart from palliative care of flare-up with anti-androgens).
  • Patient is unable to understand the information regarding the study provided to him, of giving his consent or who has refused to sign the sheet.
  • Patient for whom risk follow up could not be guaranteed within the conditions stipulated in the protocol or is unable to complete the self-evaluation questionnaires.
  • Diabetic, or patient with severe progressive disease: kidney, liver, cardiovascular (especially high uncontrolled BP), psychiatric.
  • Has a Thromboembolic history or concomitant thromboembolic disease.
  • Patient had hepatocellular insufficiency or hepatic cytolysis (serum glutamic oxaloacetic transaminase / serum glutamic pyruvate transaminase [/SGPT] >3 times laboratory normal range).
  • Patient had a to one of the study drugs.
  • Patient receiving corticotherapy or concomitant prescription for non-selective monoamine oxidase inhibitors (MAOI), serotonin re-uptake inhibitors, clonidine, gabapentine, veripride, tibolone or beta-alanine.
  • Patient was undergoing medical treatment for a depressive phase or had been treated for this during the previous 2 years before inclusion.
  • Patient with a history of congenital galactosemy, poor absorption of glucose or galactose syndrome or even a lactase deficiency.
  • Patient had another cancer in the 5 previous years excluding basocellular epithelioma or in situ carcinoma.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    Cyproterone acetate

    Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, cyproterone acetate 50 mg, tablet-in-capsule, along with cyproterone acetate placebo-matching capsule, orally, once daily in the morning and cyproterone acetate 50 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Cyproterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.

    Drug: Cyproterone acetate · Drug: Leuprorelin · Drug: Flutamide · Drug: Placebo

  • Experimental
    Medroxyprogesterone acetate

    Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, medroxyprogesterone acetate 10 mg, tablet-in-capsule, along with medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning and medroxyprogesterone acetate 10 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.

    Drug: Medroxyprogesterone acetate · Drug: Leuprorelin · Drug: Flutamide · Drug: Placebo

  • Experimental
    Venlafaxine

    Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, venlafaxine 75 mg, capsule, orally, once daily in the morning and venlafaxine placebo-matching capsule, orally, once daily in the evening for 8 weeks. Venlafaxine 37.5 mg, capsule, orally, once daily in the evening for the next 2 weeks.

    Drug: Venlafaxine · Drug: Leuprorelin · Drug: Flutamide · Drug: Placebo

Interventions

  • Cyproterone acetate tablet-in-capsule.

    Also known as: Androcur® 50 mg

  • Medroxyprogesterone acetate tablet-in-capsule.

    Also known as: Gestoral® 10 mg

  • Venlafaxine capsule.

    Also known as: Effexor® LP 37.5 mg

  • Leuprorelin injection.

    Also known as: Enantone® 11.25 mg

  • Flutamide tablet

  • DrugPlacebo

    Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.

06

What researchers measure

Primary outcomes

  1. Percent Change from Randomization in Hot Flushes (HF) Score at Week 4 of Treatment

    The change is calculated as follows: \[(HF score at Week 4 of treatment - HF score at randomization)/HF score at randomization\]\*100. The calculation of the HF score will be done as follows: a coefficient is allocated to each severity grade, it varies from 1 to 4 (1: slight; 2: moderate; 3: severe; 4: very severe), and the calculation of the daily score is equal to the sum of the daily instances of hot flushes multiplied by their severity coefficient. The score calculated at randomization and Week 4 of treatment will be the average of the scores recorded in the preceding week. The score range will depend upon the frequency of hot flushes, and higher score signifies higher severity of hot flushes.

    Time frame: Randomization (Month 6) and Week 4 of treatment (Month 7)

Secondary outcomes

  1. Percent Change from Randomization in HF Frequency at Weeks 4, 8 of Treatment and Last Available Value

    The change is calculated as follows: \[(HF frequency at specified Week of treatment - HF frequency at randomization)/HF score at randomization\]\*100.

    Time frame: Randomization (Month 6), Weeks 4 and 8 of treatment (Months 7 and 8, respectively) and last available value (Month 7 or 8)

  2. Percentage of Participants With More Than 50 percent (%) Decrease in HF Score

    The percentage of participants with at least 50 % improvement in HF score after 4 weeks of treatment compared to randomization will be calculated. The calculation of the HF score will be done as follows: a coefficient is allocated to each severity grade, it varies from 1 to 4 (1: slight; 2: moderate; 3: severe; 4: very severe), and the calculation of the daily score is equal to the sum of the daily instances of hot flushes multiplied by their severity coefficient. The score range will depend upon the frequency of hot flushes, and higher score signifies higher severity of hot flushes. The score calculated at randomization and Week 4 of treatment will be the average of the scores recorded in the preceding week.

    Time frame: Week 4 of treatment

  3. Percentage of Participants with Complete Regression of hot flushes

    Complete regression at Week 4 of treatment signifies complete disappearance of hot flushes upon 4 weeks of treatment.

    Time frame: Week 4 of treatment

  4. Percentage of Participants With A Decrease in the Level of HF Complaint

    Decrease (improvement) in the level of complaint regarding hot flushes will be assessed compared to randomization. Participants' level of complaints about hot flushes was recorded at each visit of the study. The change in the level of complaints will be classified as degradation, non-change or improvement.

    Time frame: Weeks 4 and 8 of treatment and Week 12 after the start of treatment

  5. Percent Change in HF Score from Randomization at Week 8 of Treatment and Last Available Value

    The change is calculated as follows: \[(HF score at specified Week of treatment - HF score at randomization)/HF score at randomization\]\*100. The calculation of the HF score will be done as follows: a coefficient is allocated to each severity grade, it varies from 1 to 4 (1: slight; 2: moderate; 3: severe; 4: very severe), and the calculation of the daily score is equal to the sum of the daily instances of hot flushes multiplied by their severity coefficient. The score range will depend upon the frequency of hot flushes, and higher score signifies higher severity of hot flushes. The score calculated at randomization and Week 8 of treatment will be the average of the scores recorded in the preceding week.

    Time frame: Randomization, Week 8 of treatment, and last available value (Month 7 or 8)

  6. Percent Change from Week 4 of treatment in HF Score at Week 8 of Treatment

    The change is calculated as follows: \[(HF score at Week 8 of treatment - HF score at Week 4 of treatment)/HF score at Week 4 of treatment\]\*100. The calculation of the HF score will be done as follows: a coefficient is allocated to each severity grade, it varies from 1 to 4 (1: slight; 2: moderate; 3: severe; 4: very severe), and the calculation of the daily score is equal to the sum of the daily instances of hot flushes multiplied by their severity coefficient. The score range will depend upon the frequency of hot flushes, and higher score signifies higher severity of hot flushes. The score calculated at Weeks 4 and 8 of treatment will be the average of the scores recorded in the preceding week.

    Time frame: Weeks 4 and 8 of treatment

  7. Percent Change from Week 4 of treatment in HF Frequency at Week 8 of Treatment

    The change is calculated as follows: \[(HF frequency at Week 8 of treatment - HF frequency at Week 4 of treatment)/HF score at Week 4 of treatment\]\*100.

    Time frame: Weeks 4 and 8 of treatment

  8. Percentage of Participants Who Wish to Continue the Treatment at the End of Week 10

    Participants will be asked at Week 8 and 12 visits if they would like to continue the study treatment beyond the protocol-specified 10 weeks of treatment.

    Time frame: Weeks 8 and 12 after the start of treatment

  9. Percentage of Participants Who Wish to Restart the Treatment at the End of Week 12

    Participants will be asked at Week 12 visit if they would like to restart the study treatment which ended after 10 weeks.

    Time frame: Week 12 after the start of treatment

  10. European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)

    EORTC QLQ-C30: includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions uses 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions uses 7-point scale (1 'very poor' to 7 'Excellent'). Scores are averaged and transformed to 0-100 scale; for the 5 functional scales and the global quality-of-life scale, a higher score represents a better level of functioning. For the symptom-oriented scales and items, a higher score corresponds to a higher level of symptoms.

    Time frame: Baseline (Month 0), randomization (Month 6), Weeks 4 and 8 of treatment, Week 12 after the start of treatment

  11. Participant's Satisfaction About Treatment

    Participant's satisfaction is assessed by asking them how they would rate the treatment efficacy as not very effective, moderately effective and very effective at 4, 8 weeks of treatment and 12 weeks after the start of treatment.

    Time frame: Week 4, 8 of treatment, and Week 12 after the start of treatment

07

Study locations

1 site
  • Professor Jacques IRANI
    Poitiers, 86021, France
08

References and documents

Publications

  • Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010 Feb;11(2):147-54. doi: 10.1016/S1470-2045(09)70338-9. Epub 2009 Dec 4. PubMed 19963436 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2009
First posted
Nov 11, 2009
Start
Apr 2004
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Last update
Jul 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01011751
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 11, 2009
Start date
Apr 2004
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Jul 30, 2015

Study contacts

jacques irani, MD
principal investigator · Poitiers hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyproterone Acetate · Medroxyprogesterone Acetate · Venlafaxine

Start the discussion